Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer

NCT03709082 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT03709082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03709082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
Lead sponsor
University of Kansas Medical Center
Phase
Phase 1/2
Overall status
Terminated
Start date
October 15, 2018
Completion date
February 3, 2021
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, her2-positive breast cancer